To identify a possible activity of PRIMA-1Met on the transactivating potential of mutant p53, the modulation of p53 (wt and mutant), MDM2, and p21, following PRIMA-1Met exposure, was assayed in OSU, MEC-1 (Figure 5), and primary CLL samples (Figure 6). The gene discussed is MDM2; the disease is B-cell chronic lymphocytic leukemia.